Our results show that HCC patients with LRP1B mutations have a higher TMB and a higher expression of immune checkpoint genes, indicating that LRP1B mutations have a certain predictive value in immunotherapy for HCC. The gene discussed is LRP1B; the disease is hepatocellular carcinoma.